Kiniksa Pharmaceuticals Q1 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Source: seekingalpha
- Earnings Beat: Kiniksa Pharmaceuticals reported a Q1 GAAP EPS of $0.27, exceeding expectations by $0.09, indicating a robust enhancement in profitability and competitive positioning in the market.
- Significant Revenue Growth: The company achieved Q1 revenue of $214.3 million, reflecting a 55.6% year-over-year increase and surpassing expectations by $8.21 million, demonstrating strong product demand and market acceptance.
- Future Revenue Guidance: Kiniksa anticipates 2026 ARCALYST net product revenue between $930 million and $945 million, an increase from the previous guidance of $900 million to $920 million, showcasing confidence in future market potential.
- Positive Cash Flow: The company expects its current operating plan to remain cash flow positive on an annual basis, indicating effective financial management and resource allocation that will support future growth strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KNSA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KNSA
Wall Street analysts forecast KNSA stock price to fall
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 62.770
Low
48.00
Averages
53.50
High
60.00
Current: 62.770
Low
48.00
Averages
53.50
High
60.00
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kymera Therapeutics Appoints New Chairman of the Board
- Board Leadership Change: Kymera Therapeutics announced the appointment of Felix J. Baker as the new Chairman of the Board, succeeding Bruce Booth, who has held the position since 2016 and will remain on the Board as an Independent Director, ensuring continuity and stability in corporate governance.
- Management Background: Baker has served as the company's Lead Independent Director since 2024 and is a Managing Member of Baker Brothers Investment, co-founded in 2000, which brings extensive experience in biopharmaceutical investments, likely providing stronger strategic guidance for Kymera.
- Stock Performance: Kymera's stock has traded between $36.65 and $105 over the past year, closing at $99.87, up 1.65% from the previous day, indicating market confidence in the company's future prospects.
- After-Hours Trading Dynamics: In after-hours trading, Kymera's shares rose 0.33% to $100.20, reflecting investor optimism regarding the new Chairman's appointment, which may further drive stable growth in the company's stock price.
See More
Kiniksa (KNSA) Q1 2026 Earnings Transcript
See More
Kiniksa Pharmaceuticals to Participate in Investor Conferences
- Investor Conference Schedule: Kiniksa Pharmaceuticals will participate in two significant investor conferences in June 2026, specifically the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, showcasing its latest advancements in the biopharmaceutical sector.
- Live Webcast Availability: The company will provide live webcasts of the presentations through the Investors & Media section of its website, ensuring that investors can access real-time information, with replays available within 48 hours post-event, enhancing transparency and information accessibility.
- Company Mission and Vision: Kiniksa is dedicated to improving patients' lives by discovering, acquiring, developing, and commercializing novel therapies, particularly focusing on cardiovascular indications, highlighting its strategic positioning in addressing unmet medical needs.
- Biopharmaceutical Market Potential: Kiniksa's portfolio is based on strong biological rationale or validated mechanisms, offering differentiation potential, indicating the company's commitment to innovation and growth in the competitive biopharmaceutical market.
See More
Kiniksa Pharmaceuticals International (KNSA.US) Officer Plans to Sell $3.14 Million in Common Stock via Form 144
Stock Sale Announcement: Paolini John F. intends to sell 58,424 shares of Kiniksa Pharmaceuticals International on May 1, with a total market value of approximately $3.14 million.
Reduction in Shareholding: Since March 2, 2026, Paolini John F. has reduced his shareholding in Kiniksa Pharmaceuticals International by 40,000 shares, valued at around $1.79 million.
See More
Enphase Energy Drops as Solar Demand Weakens
- Earnings Decline: Enphase Energy reported a 31% year-over-year drop in non-GAAP earnings per share for Q1, leading to a more than 10% decline in pre-market trading, highlighting significant challenges in the U.S. market amid tariff costs and oil-centric energy policies.
- International Market Expansion: Despite domestic struggles, CEO Kothandaraman noted healthy double-digit growth in battery demand across Europe, which is expected to drive revenue growth; however, to combat competition, the company plans to reduce distributor prices for batteries by approximately 10% in May.
- Revenue Outlook: Management anticipates Q2 revenue between $280 million and $310 million, following Q1 revenue of $282.9 million, while maintaining non-GAAP gross margins between 44% and 47%, indicating confidence in the commercialization of next-generation products.
- Intensifying Market Competition: With a prior 20% price reduction on microinverters implemented last December, the upcoming price adjustments may impact short-term margins but could pave the way for long-term market share gains, reflecting the company's adaptability in the rapidly evolving solar market.
See More
Kiniksa Pharmaceuticals Reports Strong Q1 Earnings, Shares Surge
- Strong Performance: Kiniksa Pharmaceuticals' inaugural Q1 earnings report for 2026 revealed revenue exceeding $214 million, a significant increase from last year's under $138 million, convincingly beating analyst expectations of $207 million, showcasing the company's robust performance in the biotech sector.
- Net Income Doubles: Under GAAP, Kiniksa's net income more than doubled from $8.5 million in Q1 2025 to $22.6 million, with earnings per share reaching $0.27, significantly surpassing the analyst forecast of $0.21, reflecting a marked improvement in the company's profitability.
- Product Success Drives Growth: The recent approval of Arcalyst, particularly for the heart condition pericarditis, has been a key driver of Kiniksa's popularity, prompting management to raise its 2026 net sales forecast to between $930 million and $945 million, indicating strong market demand for the drug.
- Positive Market Reaction: Following the earnings release, Kiniksa's stock surged nearly 24%, bringing its market capitalization to $3.3 billion, demonstrating investor confidence in the company's future growth potential, especially regarding the development of multiple indications for its single product.
See More
Kymera Therapeutics Appoints New Chairman of the Board
- Board Leadership Change: Kymera Therapeutics announced the appointment of Felix J. Baker as the new Chairman of the Board, succeeding Bruce Booth, who has held the position since 2016 and will remain on the Board as an Independent Director, ensuring continuity and stability in corporate governance.
- Management Background: Baker has served as the company's Lead Independent Director since 2024 and is a Managing Member of Baker Brothers Investment, co-founded in 2000, which brings extensive experience in biopharmaceutical investments, likely providing stronger strategic guidance for Kymera.
- Stock Performance: Kymera's stock has traded between $36.65 and $105 over the past year, closing at $99.87, up 1.65% from the previous day, indicating market confidence in the company's future prospects.
- After-Hours Trading Dynamics: In after-hours trading, Kymera's shares rose 0.33% to $100.20, reflecting investor optimism regarding the new Chairman's appointment, which may further drive stable growth in the company's stock price.
See More
Kiniksa (KNSA) Q1 2026 Earnings Transcript
See More
Kiniksa Pharmaceuticals to Participate in Investor Conferences
- Investor Conference Schedule: Kiniksa Pharmaceuticals will participate in two significant investor conferences in June 2026, specifically the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, showcasing its latest advancements in the biopharmaceutical sector.
- Live Webcast Availability: The company will provide live webcasts of the presentations through the Investors & Media section of its website, ensuring that investors can access real-time information, with replays available within 48 hours post-event, enhancing transparency and information accessibility.
- Company Mission and Vision: Kiniksa is dedicated to improving patients' lives by discovering, acquiring, developing, and commercializing novel therapies, particularly focusing on cardiovascular indications, highlighting its strategic positioning in addressing unmet medical needs.
- Biopharmaceutical Market Potential: Kiniksa's portfolio is based on strong biological rationale or validated mechanisms, offering differentiation potential, indicating the company's commitment to innovation and growth in the competitive biopharmaceutical market.
See More
Kiniksa Pharmaceuticals International (KNSA.US) Officer Plans to Sell $3.14 Million in Common Stock via Form 144
Stock Sale Announcement: Paolini John F. intends to sell 58,424 shares of Kiniksa Pharmaceuticals International on May 1, with a total market value of approximately $3.14 million.
Reduction in Shareholding: Since March 2, 2026, Paolini John F. has reduced his shareholding in Kiniksa Pharmaceuticals International by 40,000 shares, valued at around $1.79 million.
See More
Enphase Energy Drops as Solar Demand Weakens
- Earnings Decline: Enphase Energy reported a 31% year-over-year drop in non-GAAP earnings per share for Q1, leading to a more than 10% decline in pre-market trading, highlighting significant challenges in the U.S. market amid tariff costs and oil-centric energy policies.
- International Market Expansion: Despite domestic struggles, CEO Kothandaraman noted healthy double-digit growth in battery demand across Europe, which is expected to drive revenue growth; however, to combat competition, the company plans to reduce distributor prices for batteries by approximately 10% in May.
- Revenue Outlook: Management anticipates Q2 revenue between $280 million and $310 million, following Q1 revenue of $282.9 million, while maintaining non-GAAP gross margins between 44% and 47%, indicating confidence in the commercialization of next-generation products.
- Intensifying Market Competition: With a prior 20% price reduction on microinverters implemented last December, the upcoming price adjustments may impact short-term margins but could pave the way for long-term market share gains, reflecting the company's adaptability in the rapidly evolving solar market.
See More
Kiniksa Pharmaceuticals Reports Strong Q1 Earnings, Shares Surge
- Strong Performance: Kiniksa Pharmaceuticals' inaugural Q1 earnings report for 2026 revealed revenue exceeding $214 million, a significant increase from last year's under $138 million, convincingly beating analyst expectations of $207 million, showcasing the company's robust performance in the biotech sector.
- Net Income Doubles: Under GAAP, Kiniksa's net income more than doubled from $8.5 million in Q1 2025 to $22.6 million, with earnings per share reaching $0.27, significantly surpassing the analyst forecast of $0.21, reflecting a marked improvement in the company's profitability.
- Product Success Drives Growth: The recent approval of Arcalyst, particularly for the heart condition pericarditis, has been a key driver of Kiniksa's popularity, prompting management to raise its 2026 net sales forecast to between $930 million and $945 million, indicating strong market demand for the drug.
- Positive Market Reaction: Following the earnings release, Kiniksa's stock surged nearly 24%, bringing its market capitalization to $3.3 billion, demonstrating investor confidence in the company's future growth potential, especially regarding the development of multiple indications for its single product.
See More
